<div id="readability-page-1"><p>ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) was the recipient of a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 1,785,809 shares,  an increase of 47.2% from the January 15th total of 1,213,326 shares. Currently, 1.9% of the shares of the company are sold short. Based on an average daily volume of 439,616 shares, the days-to-cover ratio is currently 4.1 days. Based on an average daily volume of 439,616 shares, the days-to-cover ratio is currently 4.1 days. Currently, 1.9% of the shares of the company are sold short.</p><div><p><span></span><span>Get <strong>ProQR Therapeutics</strong> alerts:</span></p></div><h2>ProQR Therapeutics Trading Up 5.0%</h2><p>Shares of NASDAQ:PRQR opened at $1.46 on Friday. The firm's 50 day moving average is $1.87 and its two-hundred day moving average is $2.13. The firm has a market capitalization of $153.61 million, a P/E ratio of -3.11 and a beta of 0.20. ProQR Therapeutics has a 52 week low of $1.07 and a 52 week high of $3.10. </p><h2>Institutional Inflows and Outflows</h2><p>Large investors have recently modified their holdings of the business. Walleye Capital LLC grew its holdings in  ProQR Therapeutics by 11.2% during the fourth quarter. Walleye Capital LLC now owns 591,785 shares of the biopharmaceutical company's stock worth $1,195,000 after acquiring an additional 59,808 shares during the period.  Jane Street Group LLC grew its stake in shares of  ProQR Therapeutics by 1,388.5% in the 4th quarter. Jane Street Group LLC now owns 160,175 shares of the biopharmaceutical company's stock worth $324,000 after purchasing an additional 149,414 shares during the last quarter.  Simplex Trading LLC raised its holdings in shares of  ProQR Therapeutics by 44,169.0% in the 4th quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company's stock worth $89,000 after purchasing an additional 44,169 shares in the last quarter.  Geode Capital Management LLC lifted its stake in  ProQR Therapeutics by 73.9% during the fourth quarter. Geode Capital Management LLC now owns 84,909 shares of the biopharmaceutical company's stock valued at $172,000 after purchasing an additional 36,087 shares during the last quarter.  Finally, Privium Fund Management B.V. lifted its stake in  ProQR Therapeutics by 7.2% during the fourth quarter. Privium Fund Management B.V. now owns 5,357,762 shares of the biopharmaceutical company's stock valued at $10,823,000 after purchasing an additional 359,475 shares during the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds. </p><h2>Analyst Ratings Changes</h2><p>A number of research analysts have recently issued reports on the stock. Chardan Capital  restated a &#34;buy&#34; rating and issued a $4.00 price target on shares of ProQR Therapeutics in a research report on Tuesday, November 4th. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of ProQR Therapeutics in a research note on Thursday, January 22nd. Finally, Zacks Research upgraded ProQR Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, November 13th. Seven investment analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has given a Sell rating to the stock. Based on data from MarketBeat, ProQR Therapeutics presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $7.14.</p><p><b>View Our Latest Analysis on PRQR</b></p><h2>ProQR Therapeutics Company Profile</h2> (Get Free Report)<p>ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company's pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.  </p><p>Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.</p><h2>See Also</h2><ul><li>Five stocks we like better than ProQR Therapeutics</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>Think You Missed Silver? You’re Wrong. Here’s Why.</li><li>Trump’s AI Secret: 100X Faster Than Nvidia</li><li>Your Bank Account Is No Longer Safe</li><li>The Next Commodity Crunch (bigger than oil?)</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in ProQR Therapeutics Right Now?</h2><p>Before you consider ProQR Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProQR Therapeutics wasn't on the list.</p><p>While ProQR Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LABD

SBIO

PRQR

<p>ProQR Therapeutics N.V. (NASDAQ:PRQR) experienced a significant increase in short interest of 47.2% in January, totaling 1,785,809 shares as of January 30th. This represents approximately 1.9% of the company's stock sold short, with a days-to-cover ratio of 4.1 days based on an average daily volume of 439,616 shares. The stock opened at $1.46, with a market cap of $153.61 million. Analysts have mixed ratings, with a consensus target price of $7.14, indicating a "Moderate Buy" sentiment.</p>

ProQR Therapeutics N.V. (NASDAQ:PRQR) Short Interest Up 47.2% in January